Brief: Fulcrum Therapeutics Q4 Basic EPS USD -0.4
27/02/2024 12:00
Feb 27 (Reuters) - Fulcrum Therapeutics Q4 net income USD -24.756 million. * Q4 operating income USD -27.992 million vs. IBES estimate USD -29 million * Q4 collaboration revenue USD 871 thousand * Q4 operating expenses USD 28.863 million
Recent news on Fulcrum Therapeutics
See all newsFulcrum down after announcing restructuring, plans to cut 85% jobs
Brief: Fulcrum Therapeutics Approves Restructuring Plan After Discontinuing Pociredir For Sickle Cell Disease
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Fulcrum
U.S. STOCKS ON THE MOVE-Hewlett Packard, Alphabet, Philip Morris
Fulcrum falls after discontinuing sickle cell drug program